Zacks Research Issues Negative Estimate for CORT Earnings

Key Points

• Zacks Research cut its Q1 2026 EPS estimate for Corcept to ($0.35) (from ($0.31)) and maintains a "Strong Sell" rating, forecasting weaker FY2026/FY2027 earnings that could pressure the stock.
• Corcept recently missed quarterly expectations—EPS $0.20 vs. $0.33 consensus and revenue $202.13M vs. $254.94M—while the shares trade near $34, well below their 12‑month high.
• Director G. Leonard Baker Jr. purchased 100,000 shares (~$3.3M), boosting his stake ~9.6%, even as the company faces multiple investor lawsuits and reported FDA rejection and patent‑loss issues that increase legal and regulatory risk.

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities researchers at Zacks Research decreased their Q1 2026 earnings per share estimates for shares of Corcept Therapeutics in a research note issued to investors on Tuesday, March 17th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings per share of ($0.35) for the quarter, down from their prior estimate of ($0.31). Zacks Research currently has a "Strong Sell" rating on the stock. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics' Q4 2026 earnings at $0.40 EPS, FY2026 earnings at $0.20 EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at $0.18 EPS, Q3 2027 earnings at $0.91 EPS, Q4 2027 earnings at $0.77 EPS and FY2027 earnings at $1.67 EPS.

A number of other research analysts have also recently commented on CORT. Weiss Ratings reissued a "hold (c)" rating on shares of Corcept Therapeutics in a report on Monday, December 29th. HC Wainwright lowered their price objective on shares of Corcept Therapeutics from $105.00 to $67.00 and set a "buy" rating for the company in a research report on Friday, February 20th. UBS Group assumed coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They issued a "neutral" rating and a $95.00 price objective for the company. Canaccord Genuity Group raised their target price on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, January 23rd. Finally, Wolfe Research downgraded shares of Corcept Therapeutics from a "peer perform" rating to an "underperform" rating and set a $30.00 price target for the company. in a report on Wednesday, December 31st. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $77.17.

Corcept Therapeutics Stock Performance

Corcept Therapeutics stock opened at $34.08 on Friday. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The stock has a market cap of $3.63 billion, a PE ratio of 41.56 and a beta of 0.29. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $117.33. The business's 50-day moving average price is $37.52 and its two-hundred day moving average price is $62.18.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.13). The business had revenue of $202.13 million for the quarter, compared to analyst estimates of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.Corcept Therapeutics's quarterly revenue was up 11.1% on a year-over-year basis. During the same period last year, the firm posted $0.26 EPS.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, Director G Leonard Baker, Jr. acquired 100,000 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The stock was acquired at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the acquisition, the director directly owned 1,146,631 shares in the company, valued at $37,999,351.34. This represents a 9.55% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total transaction of $817,400.00. Following the sale, the insider owned 1,235 shares in the company, valued at approximately $50,474.45. This represents a 94.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 48,233 shares of company stock valued at $1,817,306 in the last ninety days. 20.80% of the stock is currently owned by insiders.

Institutional Trading of Corcept Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of CORT. Abacus FCF Advisors LLC bought a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at about $3,238,000. Pacer Advisors Inc. raised its position in shares of Corcept Therapeutics by 6,796.7% during the third quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company's stock worth $32,459,000 after acquiring an additional 384,896 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Corcept Therapeutics by 223.4% in the third quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company's stock worth $70,632,000 after acquiring an additional 587,053 shares during the period. Brown Capital Management LLC bought a new stake in Corcept Therapeutics in the third quarter valued at approximately $19,950,000. Finally, Cerity Partners LLC increased its position in Corcept Therapeutics by 21.4% during the 2nd quarter. Cerity Partners LLC now owns 746,593 shares of the biotechnology company's stock valued at $54,800,000 after purchasing an additional 131,799 shares during the period. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Director G. Leonard Baker Jr. purchased 100,000 CORT shares (~$3.3M) on March 17, increasing his stake by ~9.6%, a signal of insider confidence that can support the stock. SEC Form 4
• Neutral Sentiment: Reported short‑interest data show effectively zero reported short interest as of March 19 (data appear anomalous), so there’s no clear short‑seller pressure signal from this release. (May reflect reporting irregularities rather than investor behavior.)
• Negative Sentiment: Hagens Berman and other firms highlight an investor suit tied to an alleged FDA rejection and a federal court patent loss — items that can materially damage future revenue expectations and investor confidence. Hagens Berman Alert
• Negative Sentiment: Multiple shareholder‑rights firms (Schall, DJS, Rosen, Pomerantz, Glancy, Levi & Korsinsky, Robbins, etc.) issued class‑action/lead‑plaintiff notices for investors who bought CORT between Oct 31, 2024 and Dec 30, 2025 — a concentrated PR wave that keeps legal risk and potential liability top of mind for the market. Representative notice: Schall Law Firm. Schall Law Firm Notice
• Negative Sentiment: Zacks Research cut its Q3 2026 EPS estimate for CORT (from $0.30 to $0.21) and carries a "Strong Sell" view — analyst downgrades and lower guidance expectations can weigh on sentiment and valuation multiples.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.